title: Initial control of chemotherapy-induced nausea and vomiting in patient quality of life.
abstract: The side effects commonly experienced by patients receiving chemotherapy for the treatment of cancer can challenge many aspects of daily life. Nausea and vomiting, the most common side effects reported by patients, affect the ability to continue with usual life activities and, thus have a pronounced impact on quality of life. This paper reviews studies of the impact of nausea and emesis on quality of life, and highlights the importance of prevention of these side effects by presenting new data on how persistent uncontrolled nausea and vomiting can be. The Morrow Assessment of Nausea and Emesis (MANE) was used to collect information on symptoms experienced by consecutive patients starting chemotherapy between September 1987 and December 1995 at any of 18 geographically diverse member sites of the University of Rochester Cancer Center Community Clinical Oncology Program. Data from 1,413 patients were collected after each of four successive chemotherapy treatments. Reported incidences of posttreatment nausea and posttreatment vomiting after the first treatment were 59.4% and 28.6%, respectively. Occurrence of nausea/vomiting at the first treatment was a strong predictor of nausea/vomiting at later treatments. Of the 839 patients reporting initial nausea, 763 (90.9%) reported nausea at at least one subsequent treatment, and approximately 59% reported nausea after all three subsequent treatments. Fewer than half (45.6%) of the patients who had no nausea at the first treatment developed it later. The majority (72.0%) of patients reporting vomiting at the first treatment also reported subsequent vomiting, 30.7% of whom experienced emesis at all remaining treatments. Conversely, 76.2% of patients who were emesis-free at the first treatment remained so for all later treatments. These findings show a continuing need for further progress in controlling nausea and vomiting, and demonstrate the importance of aggressive nausea/vomiting control at the first treatment. In addition, more emphasis on controlling chemotherapy-induced nausea after its initial occurrence is necessary.
authors.affiliation: University of Rochester Cancer Center, New York, USA.
authors.forename: G R
authors.initials: GR
authors.lastname: Morrow
authors.forename: J A
authors.initials: JA
authors.lastname: Roscoe
authors.forename: J T
authors.initials: JT
authors.lastname: Hickok
authors.forename: R M
authors.initials: RM
authors.lastname: Stern
authors.forename: H I
authors.initials: HI
authors.lastname: Pierce
authors.forename: D B
authors.initials: DB
authors.lastname: King
authors.forename: T K
authors.initials: TK
authors.lastname: Banerjee
authors.forename: P
authors.initials: P
authors.lastname: Weiden
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004639:Emetics; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D011788:Quality of Life; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000970:Antineoplastic Agents; D004639:Emetics